Erectile Dysfunction: Medical Causes, Psychological Factors, and Every Treatment Option

Erectile dysfunction — defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual activity — affects an estimated 30 million men in the United States. Despite its prevalence, it remains one of the most underreported and undertreated conditions in men's health, largely because of the stigma and embarrassment that prevent frank clinical conversations. What most men do not realize is that erectile dysfunction is frequently not a psychological problem, not an inevitable consequence of aging, and not simply a matter of sexual confidence. For a large proportion of patients, it is a symptom of underlying cardiovascular disease, metabolic disorder, or hormonal imbalance — and it often precedes a major cardiac event by two to five years. This context reframes ED not as an embarrassing inconvenience but as clinically important information about systemic health.

How Erections Work

Erection is primarily a vascular event mediated by the nervous system. Sexual stimulation — whether physical or psychological — triggers parasympathetic nervous system activity, causing the release of nitric oxide (NO) in the penile smooth muscle and endothelium. Nitric oxide activates guanylyl cyclase, producing cyclic GMP (cGMP), which relaxes the smooth muscle of the corpus cavernosum. This relaxation allows the cavernosal arteries to dilate, flooding the erectile tissue with blood. As the tissue engorges, venous outflow is compressed against the tunica albuginea (a fibrous sheath surrounding the corpora), trapping blood and maintaining rigidity. The enzyme phosphodiesterase type 5 (PDE5) degrades cGMP, ending the erection. Any disruption along this pathway — vascular, neurological, hormonal, or pharmacological — can produce ED.

Vascular Causes

Arterial insufficiency is the single most common organic cause of erectile dysfunction. The penile arteries are small — approximately 1 to 2 mm in diameter — and are among the earliest vessels in the body to manifest atherosclerosis. The same process of plaque buildup, endothelial dysfunction, and impaired vasodilation that eventually produces coronary artery disease and stroke causes ED first, because smaller vessels become symptomatic at lower levels of disease burden. This is why a 40-year-old man with new-onset ED and no obvious explanation has a 40 to 50 percent chance of having significant coronary artery disease detectable on imaging. The Princeton Consensus guidelines explicitly frame new-onset ED in a middle-aged man without an obvious cause as a cardiac risk marker requiring cardiovascular evaluation before initiating treatment.

Risk factors for vascular ED mirror cardiovascular risk factors exactly: hypertension, hyperlipidemia, diabetes mellitus, smoking, obesity, and physical inactivity. Uncontrolled hypertension damages penile arterial endothelium directly; some antihypertensive medications (particularly older beta-blockers and thiazides) also impair erectile function, though this must be distinguished from the underlying vascular damage.

Neurological Causes

Erection requires intact neurological pathways from the brain through the spinal cord to the pelvic nerves. Conditions that damage these pathways cause neurogenic ED: spinal cord injury, multiple sclerosis, Parkinson's disease, and stroke are prominent causes. Peripheral neuropathy from long-standing diabetes damages the autonomic nerves that mediate the initial vasodilatory response. Pelvic surgery — particularly radical prostatectomy for prostate cancer, and abdominoperineal resection — risks injuring the cavernous nerves, which run immediately adjacent to the prostate and rectum. Nerve-sparing surgical technique has improved outcomes, but post-prostatectomy ED remains common, affecting 25 to 75 percent of men depending on technique, age, and baseline function.

Hormonal Causes

Testosterone is required for libido and plays a supporting role in erectile function, though its absence alone rarely causes complete ED in otherwise healthy men. Hypogonadism — testosterone deficiency — is defined by a total morning testosterone below 300 ng/dL, confirmed on two separate measurements. Low testosterone is associated with reduced sexual desire, fatigue, mood changes, reduced muscle mass, and impaired erectile quality. However, testosterone replacement alone is rarely curative for ED unless hypogonadism is the primary driver. In men with both low testosterone and ED, combining testosterone replacement with a PDE5 inhibitor is more effective than either alone. Other hormonal causes include hyperprolactinemia (elevated prolactin suppresses testosterone and libido) and thyroid dysfunction.

Psychological and Psychogenic Causes

Psychogenic ED is most common in younger men (under 40) and is typically characterized by situational erectile failure — erections occur during sleep (nocturnal penile tumescence, which indicates intact vascular and neurological function) but fail with a partner. Anxiety, depression, relationship conflict, performance anxiety, past sexual trauma, and unrealistic expectations (often shaped by pornography) are common psychological contributors. The nocturnal erection test — either formal penile tumescence monitoring or the simple stamp test — can distinguish psychogenic from organic ED when the diagnosis is unclear. Chronic psychological ED can cause secondary performance anxiety even in men whose ED is primarily organic, creating a mixed picture that requires both medical and psychological intervention.

ED as a Cardiovascular Warning Sign

The link between ED and cardiovascular disease warrants emphasis. A 2010 meta-analysis found that men with ED had a 44 percent increased risk of cardiovascular events (heart attack, stroke) compared to men without ED, independent of traditional risk factors. Men under 60 with new ED and no obvious cause have the strongest cardiovascular signal — in this group, ED is a stronger predictor of future cardiac events than family history. This does not mean every man with ED is about to have a heart attack; it means ED is a clinician's opportunity to assess cardiovascular risk comprehensively, optimize modifiable risk factors, and potentially prevent a major event.

Evaluation

A thorough ED evaluation includes medical and sexual history, physical examination, and laboratory tests. Standard labs include morning fasting total and free testosterone, complete metabolic panel, lipid panel, hemoglobin A1c (to identify undiagnosed diabetes), thyroid function, and a complete blood count. The IIEF (International Index of Erectile Function) questionnaire is a validated patient-reported outcome measure that quantifies ED severity and monitors treatment response. Specialized testing (penile duplex ultrasound, nocturnal penile tumescence monitoring, pelvic nerve studies) is reserved for complex cases where surgical intervention is being considered.

PDE5 Inhibitors: The First-Line Treatment

Phosphodiesterase type 5 inhibitors are the cornerstone of oral ED treatment and the most prescribed drugs for this indication worldwide. They work by inhibiting PDE5, the enzyme that degrades cGMP, thereby prolonging and amplifying the natural erectile response to sexual stimulation. They do not cause erections independently — sexual arousal is still required.

Sildenafil (Viagra)

Sildenafil is the original PDE5 inhibitor, with onset of action 30 to 60 minutes after ingestion and duration of 4 to 6 hours. Food, particularly a high-fat meal, delays absorption. The starting dose is typically 50 mg, adjustable from 25 to 100 mg. Response rates are approximately 70 to 80 percent in men with mild to moderate vasculogenic ED. Generic sildenafil became available in the US in 2017 and has dramatically reduced cost.

Tadalafil (Cialis)

Tadalafil has a substantially longer duration of action — 24 to 36 hours, earning it the "weekend pill" description. Unlike sildenafil, its absorption is not significantly affected by food. It is available in an as-needed dose (5–20 mg) and as a daily low dose (2.5–5 mg), the latter of which improves erectile function continuously and is also FDA-approved for benign prostatic hyperplasia (BPH). Men who prefer spontaneous rather than timed sexual activity often prefer tadalafil. Tadalafil also has the advantage of lower visual side effects (PDE6 inhibition, which can cause blue-tinge visual disturbance, is lower with tadalafil than sildenafil).

Contraindications

PDE5 inhibitors are absolutely contraindicated with nitrate medications (nitroglycerin, isosorbide mononitrate/dinitrate), as the combination can produce severe, life-threatening hypotension. This is clinically important because many men with ED and cardiovascular disease are on nitrates. The Princeton Consensus III guidelines provide a framework for risk stratification of sexual activity in cardiac patients and guidance on when PDE5 inhibitors can be safely prescribed.

Vacuum Erection Devices

Vacuum erection devices (VEDs) create negative pressure around the penis, drawing blood into the corpus cavernosum, followed by a constriction ring at the base to maintain the erection during intercourse. They are effective (approximately 70 percent of users achieve satisfactory erections) and carry no systemic side effects. They are particularly valuable for men who cannot use PDE5 inhibitors due to cardiac medications, and they are sometimes used as penile rehabilitation therapy following radical prostatectomy. The primary drawbacks are the mechanical nature of use (which some couples find disruptive) and the slightly unnatural quality of the erection (the penis tends to be cool and pivot at the base rather than from the pelvis).

Penile Injections (Intracavernosal Therapy)

Intracavernosal injection (ICI) therapy — injecting vasoactive agents directly into the corpus cavernosum — produces reliable erections in 70 to 90 percent of men, including many who do not respond to PDE5 inhibitors. The most commonly used agents are alprostadil alone (Caverject, Edex) or combination formulations containing alprostadil, papaverine, and phentolamine (trimix). Erections typically begin within 5 to 20 minutes and last 30 to 60 minutes. Proper injection technique is taught in clinic. Side effects include mild penile pain (particularly with alprostadil alone), occasional bruising, and the rare but serious complication of priapism — a prolonged, painful erection lasting more than four hours that requires emergency treatment to prevent permanent damage. Men using ICI should have a clear plan for managing priapism.

Penile Implants

Penile prostheses (implants) are the most invasive treatment option but offer the highest long-term patient satisfaction among surgical interventions — approximately 90 to 95 percent satisfaction in both patients and partners. Implants are appropriate for men with severe organic ED who have not responded to, or are not candidates for, less invasive treatments. The inflatable three-piece penile prosthesis — with cylinders in the corpora, a pump in the scrotum, and a reservoir in the pelvis — is the gold standard. When inflated, it produces an erection indistinguishable from natural. Infection and mechanical failure are the main complications, with mechanical failure rates below 5 percent at five years in modern devices. Implantation destroys natural erectile tissue, so the decision is irreversible.

Testosterone Replacement

When ED is accompanied by documented hypogonadism (morning testosterone consistently below 300 ng/dL with symptoms), testosterone replacement therapy (TRT) is appropriate. TRT is available as topical gel (AndroGel, Testim), transdermal patch, intramuscular injection, subcutaneous pellets, or nasal gel. TRT does not replace a PDE5 inhibitor in men whose ED has a significant vascular component — the two are complementary. Men on TRT require monitoring of hematocrit (TRT can increase red cell mass), PSA, and lipid profile.

Psychogenic ED Treatment

Psychogenic ED responds well to cognitive-behavioral therapy (CBT), sex therapy, and couples counseling. Reducing performance anxiety — the cycle of anticipatory fear that a previous failure will recur — is central to treatment. Mindfulness-based approaches have emerging evidence. Some men with primarily psychogenic ED benefit from a short trial of a PDE5 inhibitor not as long-term treatment but as a confidence-building intervention: successfully achieving erections breaks the anxiety cycle and can enable natural function to recover.

Lifestyle Changes That Improve ED

Among modifiable risk factors, the evidence for specific interventions is robust: regular aerobic exercise (150 minutes per week) improves erectile function with an effect size comparable to PDE5 inhibitors in men with mild to moderate ED; smoking cessation improves penile endothelial function within months; weight loss in obese men (particularly when BMI is above 30) significantly improves testosterone levels and erectile function; aggressive management of hypertension, diabetes, and hyperlipidemia reduces vascular damage; and reducing alcohol consumption (heavy alcohol use acutely and chronically impairs erectile function) produces measurable benefit.

When to See a Doctor

If you have experienced ED for more than a few months — even intermittently — a medical evaluation is worth having, not only for sexual health but for cardiovascular risk assessment. It is also appropriate to discuss any new medications you are taking, as many common drugs (antidepressants, antihypertensives, antiandrogens) contribute to ED. JourneyDoctors connects you with trained specialists from $19. Start a consultation today — no waiting room, no referral needed.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment.

Frequently Asked Questions

Is erectile dysfunction a normal part of aging?

ED becomes more prevalent with age — affecting roughly 40 percent of men at 40 and 70 percent of men at 70 — but it is not an inevitable, untreatable consequence of aging. Age-related increases in ED reflect the accumulating burden of cardiovascular risk factors, declining testosterone, and comorbid conditions, most of which are modifiable. ED at any age warrants evaluation rather than acceptance as a fixed consequence of getting older.

Can antidepressants cause erectile dysfunction?

Yes. SSRIs and SNRIs — among the most commonly prescribed antidepressants — cause sexual dysfunction including reduced libido, delayed ejaculation, and erectile dysfunction in an estimated 30 to 70 percent of users. Bupropion (Wellbutrin) has the lowest sexual side effect profile among antidepressants. If antidepressant-related ED is affecting quality of life, discussing a medication switch or adding a PDE5 inhibitor with your prescriber is appropriate and should not be dismissed as less important than mental health treatment.

Do PDE5 inhibitors like Viagra work for everyone?

PDE5 inhibitors are effective in approximately 70 to 80 percent of men with mild to moderate vasculogenic ED. They are less effective in severe arterial disease, neurogenic ED (though they still work for many post-prostatectomy patients), and in men with very low testosterone (who may need TRT to optimize response). Non-response to one agent in the class does not mean another will not work; sildenafil non-responders sometimes respond to tadalafil. Ensuring optimal conditions — taking on an empty stomach, adequate sexual stimulation, appropriate dose — before concluding treatment failure is important.

Is ED a sign of low testosterone?

Low testosterone can contribute to ED but is not the most common cause. Studies suggest that fewer than 5 percent of ED cases are primarily attributable to hypogonadism. Most ED, particularly in middle-aged and older men, is vascular in origin. Testing testosterone is a routine part of the ED workup, and treating confirmed hypogonadism is appropriate — but testosterone replacement alone is often insufficient without addressing the vascular component.

Can lifestyle changes alone cure ED?

For some men — particularly those with mild ED whose primary drivers are obesity, sedentary lifestyle, heavy alcohol use, or smoking — lifestyle modification alone can produce significant or complete improvement. A landmark randomized trial found that a structured exercise and weight loss intervention achieved normal erectile function in one-third of obese men with ED, without any pharmacological treatment. For men with moderate to severe vascular ED, lifestyle changes improve but rarely completely resolve the condition without adjunctive medical treatment.